news
Novartis licenses innovative treatment for Huntington’s disease
Novartis has teamed up with PTC Therapeutics to develop PTC518, a groundbreaking treatment that targets the cause of Huntington's disease, offering new hope for patients.
List view / Grid view
Small Molecules
news
FDA greenlights AI-developed drug targeting solid tumors
Insilico Medicine’s AI-designed drug ISM5939 has received FDA IND clearance for treating solid tumours. By targeting ENPP1, it enhances anti-tumour immunity and is set to begin Phase I trials soon.
article
Chemical choreography: orchestrating complex API syntheses
Small molecules are essential for developing effective medicines, but their structural complexity and material behaviour present difficulties. In this article, Chris Brown, Senior Chemist, Onyx Scientific Ltd, discusses how the right technologies and approaches can enhance drug development and mitigate risk from initial phase to commercial launch.
news
Small molecule inducers of trained immunity found
Researchers screened over 2,000 small molecules and have now more than doubled the known compounds reported to induce trained immunity.
news
Discovery of a promising agonist adjuvant
PVP-037, identified through a small molecule screen, induces a more durable and broader immune response to vaccines.
podcasts
Small molecules for regenerative medicine
In this episode, we discuss how new insights into stem cell biology are leading to novel therapeutics in regenerative medicine beyond cell therapy.
news
Discovery enables further investigation into new ligases
Researchers have developed a new PROTAC that activates the protein degradation system and binds to a previously inaccessible ligase.
news
New technology to effectively regulate gene expression
A new strategy enables researchers to be more precise in the control of gene expression of a therapeutic protein.
article
The effectiveness of nanoparticles in chemotherapy
Understanding more about the effect of liposome nanoparticles on the immune system will improve drug delivery systems.
news
Potential of small molecule therapeutics for Barth syndrome
Novel findings about the tafazzin gene offers a potential new target and drug candidate for Barth syndrome.
news
Rare genetic variant blocks common Alzheimer’s disease risk factor
New understanding of “Christchurch mutation” in the APOE gene may lead to novel Alzheimer's disease treatments.
news
Dynamic molecular aggregates within cells
Researchers from the University of Freiburg and the University of Cambridge have observed live cell formation of membraneless molecular aggregates, uncovering the interplay between biological mechanisms and physical force.
webinar
Functional assays for the development of agonistic antibodies
20 July 2023 | By Eurofins DiscoverX
Watch this webinar to discover qualified bioassays assessing therapeutic antibody mechanisms, case studies about agonistic effects in antibodies initially deemed antagonistic, and explore Fc receptor impacts on antibody response in co-culture assays.
article
Condensate biology: advancing drug discovery for complex diseases
In this interview with Drug Target Review’s Izzy Wood and Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, discuss the innovative potential of condensate biology in revolutionising drug discovery. By targeting disease-driving condensates, Dewpoint’s research pushes boundaries by offering new hope for tackling diseases like ALS and colorectal cancer.
whitepaper
Application note: Novel screening tools for TMEM175 drug discovery
In this article, learn about how TMEM175 is an exciting new target in normal physiology and in disease. Also, read about how the use of biomarkers in Alzheimer’s drug development will address many of the challenges currently encountered.